Bausch Health Cos Inc. (NYSE:BHC) Receives Average Recommendation of “Hold” from Analysts

Shares of Bausch Health Cos Inc. (NYSE:BHC) have received a consensus recommendation of “Hold” from the six research firms that are currently covering the firm, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a hold rating. The average 12-month price target among brokers that have covered the stock in the last year is $8.50.

A number of research firms have issued reports on BHC. Wall Street Zen downgraded Bausch Health Cos from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 17th. Barclays began coverage on shares of Bausch Health Cos in a report on Monday, December 8th. They set an “equal weight” rating and a $8.00 price objective on the stock. Raymond James Financial reissued a “market perform” rating on shares of Bausch Health Cos in a research report on Monday, January 26th. Truist Financial raised their price objective on shares of Bausch Health Cos from $7.00 to $8.00 and gave the stock a “hold” rating in a report on Wednesday, January 7th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Bausch Health Cos in a report on Monday, December 29th.

Bausch Health Cos Stock Performance

Shares of BHC stock opened at $5.64 on Thursday. The company has a debt-to-equity ratio of 57.48, a quick ratio of 0.97 and a current ratio of 1.30. The firm has a market cap of $2.09 billion, a price-to-earnings ratio of 5.84 and a beta of 0.42. Bausch Health Cos has a 52 week low of $4.25 and a 52 week high of $8.69. The firm’s 50-day simple moving average is $6.83 and its two-hundred day simple moving average is $6.72.

Institutional Investors Weigh In On Bausch Health Cos

Several hedge funds and other institutional investors have recently modified their holdings of BHC. Northwestern Mutual Wealth Management Co. grew its stake in Bausch Health Cos by 6,661.3% during the third quarter. Northwestern Mutual Wealth Management Co. now owns 5,409 shares of the company’s stock valued at $35,000 after acquiring an additional 5,329 shares in the last quarter. Russell Investments Group Ltd. increased its holdings in shares of Bausch Health Cos by 65.9% in the second quarter. Russell Investments Group Ltd. now owns 7,819 shares of the company’s stock worth $51,000 after purchasing an additional 3,106 shares during the period. Camelot Portfolios LLC bought a new position in shares of Bausch Health Cos in the fourth quarter worth $59,000. Alpha Wealth Funds LLC purchased a new stake in shares of Bausch Health Cos in the second quarter worth $65,000. Finally, Concurrent Investment Advisors LLC bought a new stake in Bausch Health Cos during the fourth quarter valued at $70,000. 78.65% of the stock is currently owned by institutional investors.

Bausch Health Cos Company Profile

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.